Journals / Klinik Psikofarmakoloji Bülteni / 2012 / Cilt: 22 - Sayı: 4

Uzatılmış salınımlı ketiapin kullanımında nöroleptik malign sendrom: Olgu sunumu

Neuroleptic malignant syndrome during the use of extended release quetiapine: a case report

Pages
352–354
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study, we present a 50 year old woman with NMS that occurred during the use of extended release quetiapine, who had been diagnosed with atypical psychotic disorder for 5 years.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Neuroleptic malignant syndrome (NMS), is a potentially life-threatening condition which is rarely seen during antipsychotic use.
📊
Key Findings & Data:Hyperthermia, muscular rigidity, tremor, autonomic dysfunction, an increase in serum creatine phosphokinase levels, leukocytosis, and altered mental status can be seen in this syndrome.
💡
Conclusion & Impact:In this study, we present a 50 year old woman with NMS that occurred during the use of extended release quetiapine, who had been diagnosed with atypical psychotic disorder for 5 years.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Neuroleptic malignant syndrome (NMS), is a potentially life-threatening condition which is rarely seen during antipsychotic use. Neuroleptic malignant syndrome is characterized by the imbalance of central neurotransmitters, in which a dopaminergic block is developed. Hyperthermia, muscular rigidity, tremor, autonomic dysfunction, an increase in serum creatine phosphokinase levels, leukocytosis, and altered mental status can be seen in this syndrome. In this study, we present a 50 year old woman with NMS that occurred during the use of extended release quetiapine, who had been diagnosed with atypical psychotic disorder for 5 years.

Özet

Nöroleptik malign sendrom (NMS), antipsikotiklerin kullanımı sırasında nadir görülen, potensiyel olarak yaşamı tehdit eden bir durumdur. NMS, dopaminerjik reseptörlerde blokaj gelişmesi ve santral nörotransmitterlerde dengesizlik oluşumu ile karakterize bir sendromdur. Bu sendromda hipertermi, kas rijiditesi, tremor, otonomik disfonksiyon, serum kreatin fosfokinazda yükselme, lökositoz ve bilinç değişiklikleri görülebilir. Bu yazıda, 5 yıldır atipik psikotik bozukluk tanısıyla takip edilen 50 yaşındaki kadın hastada uzatılmış salınımlı ketiapin kullanımı sırasında ortaya çıkan NMS olgusu sunulmuştur.

🔖

Cite This Article

KARLIDAĞ, G. E., DEMİREL, İ., ÜSTÜN, C., AKYÜZ, F., OFLAZ, S. (2022). Uzatılmış salınımlı ketiapin kullanımında nöroleptik malign sendrom: Olgu sunumu. Klinik Psikofarmakoloji Bülteni, Cilt: 22 - Sayı: 4, 352–354. https://ajindex.com/articles/574111

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Margetic´ B, Margetic´ BA. Neuroleptic malignant syndrome and its controversies. Pharmacoepidemiol Drug Saf 2010;19(5):429-35
  2. Moscovich M, Nóvak FTM, Fernandes AF, Bruch T, Tomelin T, Nóvak EM, Munhoz RP, Teive HAG. Neuroleptic malignant syndrome. Arq Neuropsiquiatr 2011;69(5):751-5
  3. Friedman LS, Weinrauch LA, D’Elia JA. Metoclopramide-induced neuroleptic malignant syndrome. Arch Intern Med 1987;147(8):1495-97
  4. Pelonero A, Levenson J, Pandurangi A. Neuroleptic malignant syndrome: a review. Psychiatric Services 1998;49(9):1163-72
  5. Gillman PK. Neuroleptic malignant syndrome: mechanisms, interactions, and causality. Mov Disord 2010;25(12):1780-90
  6. Meterissian GB. Risperidon-induced neuroleptic malignant syndrome: A case report and review. Can J Psychiatr 1996;41(1):52-4
  7. Berardi D, Dell’Atti M, Amore M, De Ronchi D, Ferrari G. Clinical risk factors for neuroleptic malignant syndrome. Hum Psychopharmacol 2002;17(2):99-102
  8. Viejo LF, Morales V, Puñal P, Pérez JL, Sancho RA. Risk factors in neuroleptic malignant syndrome. A case-control study. Acta Psychiatr Scand. 2003;107(1):45-9
  9. El-Gaaly S, St John P, Dunsmore S, Bolton JM. Atypical neuroleptic malignant syndrome with quetiapine: a case report and review of the literature. J Clin Psychopharmacol 2009;29(5):497-9
  10. Solomons K. Quetiapine and neuroleptic malignant syndrome. Can J Psychiatry 2002;47(8):791
  11. American Psychiatric Association.Medication-induced movement disorders: neuroleptic malignant syndrome. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. American Psychiatric Association: Washington D.C., 2000;795-8
  12. Chan LG, Lee J, Ng BT, Chua HC, Sim K. Rare neuropsychiatric sequelae following neuroleptic malignant syndrome: A case report and review of the literature. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(8):1998-9
  13. Stanfield SC, Privette T. Neuroleptic malignant syndrome associated with olanzapine therapy: a case report. J Emerg Med 2000;19(4):355-7
  14. Reulbach U, Dütsch C, Biermann T, Sperling W, Thuerauf N, Kornhuber J, Bleich S. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care 2007;11(1):4.